# Cogent Biosciences, Inc. (COGT)

> Source: Nexqual · https://nexqual.com/COGT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Cogent Biosciences, Inc. (COGT), nexqual.com/COGT" · informational, not investment advice.

**Price:** USD 29.51 (+4.83% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 28.15 · day 28.33–29.78 · 52w 13.78–43.73 · market cap $5.12B · NMS

## Key facts
- Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 55.82 (range 45–62).
- Total return with dividends: 1Y +80.4% vs S&P 500 +18.1%; 5Y +219.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.55, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 55.82 (low 45, high 62).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-16 | Wedbush | Reiterated | Outperform | $55 |
| 2026-09-15 | HC Wainwright & Co. | Reiterated | Buy | $55 |
| 2026-08-17 | Piper Sandler | Target raised | Overweight | $52 → $55 |
| 2026-08-12 | Guggenheim | Target raised | Buy | $45 → $52 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +80.4% | +219.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +80.7% | +26.1% |
| Volatility (annualized) | 91.2% | 85.2% |
| Max drawdown | -34.4% (Aug 2026→Oct 2026) | -74.0% (Sep 2022→Apr 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/COGT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt